<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04537767</url>
  </required_header>
  <id_info>
    <org_study_id>ES-01</org_study_id>
    <nct_id>NCT04537767</nct_id>
  </id_info>
  <brief_title>The Effect of Esmolol on Patients With Sepsis</brief_title>
  <official_title>The Effect of Esmolol on Patients With Sepsis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators conduct an RCT to explore the efficacy of esmolol in patients with septic&#xD;
      shock and sepsis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe sepsis, septic shock, and their complications have become the major healthcare problem&#xD;
      that affects millions of people each year, resulting in high mortality rates. Septic&#xD;
      responses have an extremely complex chain of events including inflammatory and&#xD;
      anti-inflammatory processes, humoral and cellular reactions, and cardiocirculatory&#xD;
      abnormalities. Esmolol may have some potential in treating septic shock and sepsis. The&#xD;
      investigators conduct an RCT to explore the efficacy of esmolol in patients with septic shock&#xD;
      and sepsis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">September 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">March 31, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>REE</measure>
    <time_frame>Day 7 after enrollment</time_frame>
    <description>Resting energy expenditure</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>28-day mortality rate</measure>
    <time_frame>Day 28 after enrollment</time_frame>
    <description>28-day mortality rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HR control rate</measure>
    <time_frame>24 hours after enrollment</time_frame>
    <description>target heart rate control rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Vasoactive drug administration dose</measure>
    <time_frame>Day 1/3/7 after enrollment</time_frame>
    <description>Vasoactive drug administration dose</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concentration of Lac</measure>
    <time_frame>Day 1/3/7 after enrollment</time_frame>
    <description>Concentration of lactic acid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>O2ER</measure>
    <time_frame>Day 1/3/7 after enrollment</time_frame>
    <description>oxygen extraction rate</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">120</enrollment>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>ES group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomly assigned to the ES group were treated with esmolol to control the heart rate to the target range.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomly assigned to the control group were treated with placebo.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Esmolol</intervention_name>
    <description>The protocol required a titrated esmolol infusion commenced at 25 mg/ h, with an upper dose limit of 2000 mg/h, to maintain the HR between 75 and 90 bpm in ES group. The control group were treated with placebo.</description>
    <arm_group_label>ES group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  sepsis patients&#xD;
&#xD;
          -  HR&gt;100bpm 6h after admission&#xD;
&#xD;
          -  with CVC and ScvO2&gt;65%&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age &lt;18 years,&#xD;
&#xD;
          -  used Î²-blocker before,&#xD;
&#xD;
          -  cardiac dysrhythmias,&#xD;
&#xD;
          -  need for an inotropic agent,&#xD;
&#xD;
          -  valvular heart disease,&#xD;
&#xD;
          -  hemoglobin&gt;6g/L&#xD;
&#xD;
          -  pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>June 14, 2020</study_first_submitted>
  <study_first_submitted_qc>September 2, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 3, 2020</study_first_posted>
  <last_update_submitted>September 2, 2020</last_update_submitted>
  <last_update_submitted_qc>September 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>sepsis</keyword>
  <keyword>septic shock</keyword>
  <keyword>esmolol</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Toxemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esmolol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

